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Abstract
Background: Little is known about sex-specific trends in lung cancer mortality and years of potential life lost (YPLL)
attributable to lung cancer over more than five decades. The aim of the present study was to describe mortality
and YPLL due to lung cancer over 61 years of observation in a country with a high smoking prevalence.
Methods: We obtained data on trends in lung cancer mortality, population-level vital statistics, sales of taxed
tobacco products, and survey data on smoking behavior among the German population. We then undertook
joinpoint regression analyses to determine sex-specific trends in lung cancer mortality and YPLL.
Results: Rates of lung cancer mortality and rates of lung cancer among all causes of death increased more among
females than among males. Although YPLL among females increased from 6.6 in 1952 to 11.3 in 2012, this figure
was found to have decreased from 7.3 to 4.4 among males in the same period. Sales of tobacco subject to tax
increased from 1,509 cigarette equivalents per resident aged 15 or older in 1952 to 2,916 in 1976 — after which
there was a decline. The prevalence of current smoking among females aged 35 years or older remained stable
between 17.9 and 18.9 % in the period from 1989 to 2009. Among males in the same age group, however,
prevalence decreased from 36.7 % in 1989 to 27.5 % in 2009.
Conclusions: Lung cancer mortality and YPLL among females increased over the six decades studied. Women
should be more considered in smoking policies.
Keywords: Lung cancer, Smoking prevalence, Tobacco consumption, Age at death, Years of potential life lost
Background
Lung cancer rates among European women have been
on the rise since 1970 or even earlier in some countries
[1]. Data revealed that these are predicted to rise further
over time [2]. Despite this general trend, some countries
have observed decreases, however [3]. In the case of the
United States, previous work has shown that only three
states experienced a significant decline in female lung
cancer mortality rates during the period 1996 to 2005.
Among these, the most significant decrease was experi-
enced in California, where efforts to prevent tobacco-
related cancers have received high priority [4]. Among
males, however, declines in lung cancer mortality rates
have been reported for the majority of US states [4].
Moreover, age-adjusted lung cancer mortality rates in
the United States among men decreased at an annual
rate of two percentage points from 1996 to 2005 [4].
Previous work has shown that lung cancer results in
the second highest number of years of potential life lost
(YPLL) from among the 30 leading diseases according to
this measure in the United States [5] while the number
of YPLL is higher for lung cancer than any other cancer
[6, 7]. YPLL, defined as the difference between mean
ages at death of the general population and, in this case,
those of lung cancer patients, is a largely unbiased esti-
mate of the disease burden within a population. Trends
in overall YPLL on the population level are dependent
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on changes in rates of cause-specific and total mortality
[8]. Lung cancer mortality rates may ostensibly increase
if mortality from other causes of death decreases [8].
Although little is known about sex-specific YPLL due
to lung cancer, previous studies have found higher esti-
mates of YPLL for females diagnosed with lung cancer
than for males. In Canada, using data from the general
population in which estimated life expectancy at birth
was 82 for women and 77 for men in 2000, it was found
that cases of lung cancer in females resulted in 13.9
YPLL but only 6.8 YPLL in males [9, 10].
Recent data show that, among current tobacco
smokers, females bear a relative lung cancer risk similar
to that of males when compared with never smokers,
and that the relative risk among both females and males
aged 55 to 64 years was 19 [11]. According to a pooled
analysis of five cohort studies that included data from
the period 2000 to 2010, age-adjusted risk estimates for
lung cancer among female current smokers compared
with female never smokers increased from 2.7 in the first
half of the 1960s to 12.6 in the 1980s to 26.2 in the
2000s; with the former result approaching the equivalent
risk estimate for men of 27.3 in the same time period
[12]. Another study employing cohort data from the
general population also found no difference in lung can-
cer mortality between male and female smokers who
had continued to smoke over a 10-year survey period
[13]. This increase in risk has been explained by de-
creases in mortality among non-smoking women and by
increases in lifetime tobacco consumption among the fe-
male smokers when compared with that of male
smokers [12].
One limitation of the current evidence to date is that
evidence so far does not include changes in YPLL over
periods longer than five decades — a period that may
provide insight in trends of lung cancer mortality and
YPLL, in potential effects from public health efforts in
international comparison, and in time trends of lung
cancer among female smokers who have been shown to
follow their own stages of the tobacco epidemic com-
pared to male smokers [14]. We therefore sought (1) to
examine how and whether lung cancer mortality and
YPLL among female and male residents at age 35 or
older changed during the period 1952 to 2012 in a coun-
try with a high smoking prevalence and little efforts of
public health, and (2) to estimate tobacco consumption
using annual data on sales of tobacco products over the
entire observation period of six decades and survey data
from single years between 1989 and 2009.
Methods
We used German vital statistics data covering the years
1952 to 2012 to estimate the number of lung cancer
deaths over this period. Given that the Federal Republic
of Germany (with 33.5 million residents aged 35 or older
in 1988) reunited with the former German Democratic
Republic (with 8.3 million residents aged 35 or older in
1988) in 1990, only data from the Federal Republic of
Germany could be obtained for the period 1952 to 1990.
For the subsequent time period, from 1991 to 2012, we
used data for the reunified Germany. This aggregated
data included total numbers of deaths by diagnostic
group per calendar year and age at death among resi-
dents aged 35 years — given as numbers for each in 5-
year age band. For the calculation of mortality, we used
the number of residents per calendar year. We analyzed
cases categorized under the diagnostic group “cancer of
the trachea, bronchus and lung”. This diagnostic group
existed throughout the period studied, from 1952 to
2012. In the period 1952 to 1967 it was equivalent to the
diagnosis code 223 (“cancer of the trachea, bronchus
and lung”) in ICD-6 and ICD-7, in the period 1968 to
1997 it was equivalent to the diagnostic code 162 in
ICD-8 and ICD-9, and since 1998 has been categorized
under codes C33 (“cancer of the trachea”) and C34
(“cancers of the bronchus and lung”) in ICD-10 [15]. In
the present study, therefore, we include cancers of the
trachea, bronchus, and lung under our definition of lung
cancer.
We used the tobacco tax statistics of the Federal Stat-
istical Office as a proxy for tobacco sales. These data
provided quantities of all taxed tobacco products (TTP)
sold per calendar year from 1952 to 2012, including
number of cigarettes, number of cigars or small cigars,
fine-cut tobacco, and pipe tobacco [16, 17]. We trans-
formed number of cigars or small cigars, tons of fine-cut
tobacco and tons of pipe tobacco into cigarette equiva-
lents using one gram of fine-cut or pipe tobacco as one
cigarette equivalent and one cigar or small cigar as two
cigarette equivalents according to standard conventions
used by the Organization for Economic Co-operation
and Development [18]. We then calculated the mean
number of cigarette equivalents consumed per resident
aged 15 or older for each of the 61 calendar years.
Data on smoking status in the general population of
Germany were provided by the microcensus [19]. The
microcensus is a nationwide survey that is administered
for the federal government on a regular basis and par-
ticipation is mandatory for all residents by law. The sur-
vey includes a range of general questions such as
number of residents per household. In the years 1989,
1995, 1999, 2003, 2005 and 2009, the microcensus in-
cluded a section with questions on smoking status which
was answered on a voluntary basis. In the present study,
we made use of the data which was made available for
scientific purposes, comprising a random subsample of
70 % of the microcensus participants from each year
[19]. There was no requirement for ethics committee
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approval because the microcensus had been established
by national law. All data we used were anonymous. The
response rate to the microcensus in each year ranged
from 95 to 97 % of all households that had been ran-
domly selected for survey. We analyzed data from indi-
viduals aged 35 or older who had been addressed for
smoking questions. Among these residents, the response
rates to the question on current smoking status were
84.5 % in 1989, 90.2 % in 1995, 85.4 % in 1999, 84.5 % in
2003, 83.8 % in 2005, and 80.9 % in 2009.
We then carried out a descriptive data analysis for
each of the 61 years from 1952 to 2012 with results
stratified by sex. We estimated mortality rates and the
proportions of deaths attributable to lung cancer among
all death cases at age 35 or older. Mortality rates were
estimated separately for each of the 61 calendar years as
the number of lung cancer deaths among residents aged
35 or older per 100,000 population in the same age
group. To calculate the mean age at death we used the
mean age from each 5-year age band (i.e. 37.5 for those
aged from 35 to less than 40 years). For those who were
deceased at age 90 or older we assumed 92.5 years as
the mean age given that mortality data from the general
population indicated that the mean age at death among
both men and women aged 90 or older in 1956 was
92 years. Although this was found to have remained un-
changed in 1960, this increased to 93 for both men and
women in the period 1970 to 1993, and to 93 for males
and 94 for females in 2003. YPLL were calculated as the
mean age at death of the general population deceased at
age 35 or older excluding lung cancer deaths cases
minus the mean age at death for those whose death was
attributable to lung cancer. Due to rounding, however,
the exact mean age at death among the general popula-
tion could not be determined in any case using the avail-
able data. We then calculated the ratio of female lung
cancer deaths to male lung cancer deaths.
We analyzed trends in mortality using joinpoint re-
gression analysis using the Joinpoint Regression Pro-
gram, Version 4.1.1 [20, 21]. Results were expressed in
terms of annual percentage changes in mortality rates,
the proportion of all deaths attributable to lung cancer
among all deaths per year, and YPLL. To ensure the
maximum detail for the evolution of each trend, we se-
lected a maximum of 4 joinpoints. We defined decreases
and increases in each outcome measure by significant
annual percent changes. We assumed no change or a
stabilization had occurred if no significant changes were
found. While each of the 61 years from 1952 to 2012
was included in our regression analyses, Tables 1 and 3
show the results for every third year for the sake of read-
ability. Using responses to the questions in the micro-
census surveys pertaining to smoking, we estimated the
proportions of ever smokers and quit rates among the
general population aged 35 years or older. For the pur-
poses of the present study, ever smokers included
current and former smokers and former smokers were
defined as those who responded “No” to the question
pertaining to current smoking but “Yes” to the question
regarding whether they had previously been a smoker.
Finally, daily smokers where those respondents who in-
dicated that they smoked regularly. Age of onset of
smoking was ascertained by a question regarding age at
which the respondent started to smoke. Responses to
the question on daily cigarettes consumption were given
categorically. Quit rates in each year were calculated
using the proportion of former smokers from among
those identified as ever smokers.
Results
The lung cancer mortality rate among females increased
from 9.38 per 100,000 population in 1952 to 54.28 in
2012 with annual increases in 52 of the 61 years of ob-
servation interrupted by a period of stabilization from
1964 to 1972 (Tables 1 and 2). The estimated annual in-
crease during the period 1987 to 2012 was 2.5 percent-
age points. Among males, however, annual increases
occurred until 1985 after which there was a decrease
followed by a stabilization in the number of deaths per
100,000 population. Lung cancer deaths as a proportion
of total deaths among females increased during 54 of the
61 years studied from 0.6 % in 1952 to 3.3 % in 2012 —
implying a more than five-fold increase. Among males,
the proportion of deaths attributable to lung cancer
among all deaths increased from 2.6 % in 1952 to 7.7 %
in 2001 — a three-fold increase. This was followed by a
decline, however, which continued until 2012. The ratio
of female to male lung cancer deaths was 0.21 in 1952,
0.15 in 1973 and 0.50 in 2012.
The number of YPLL among females who died of lung
cancer rose in each year, except for the period 1960 to
1978, from 6.6 in 1952 to 11.3 in 2012. Among males,
YPLL decreased to 2.5 in 1977, increased from 1978 to
1989, decreased thereafter, and subsequently stabilized
in the period 2006 to 2012. Mean age at death among
the female lung cancer cases was 63.9 in 1952 and 70.5
in 2012, while among females in the general population
these figures were 70.4 in 1952 and 81.8 in 2012. Mean
age at death among the male lung cancer cases was 61.6
in 1952 and 70.9 in 2012, compared with 68.9 in 1952
and 75.3 in 2012 among males in the general population.
TTP increased from 1,509 cigarette equivalents per
resident aged 15 or older in year 1952 to 2,919 in 1971 —
after which it remained stable until 2001 followed by a de-
crease from 2002 to 2012 (Table 3). Rates of current
smoking among the national population aged 35 or older
were 17.9 % in 1989 and 18.9 % in 2009 for females and
36.7 % in 1989 and 27.5 % in 2009 for males (Table 4).
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Table 1 Lung cancer deaths
Year Women Men
N Lung cancer deaths/100,000
population




YPLLa N Lung cancer deaths/100,000
population




YPLLa Lung cancer deaths
women : men
1952 1,322 9.38 0.55 63.9 6.6 6,261 55.83 2.63 61.6 7.3 0.21
1955 1,531 10.47 0.60 64.1 7.3 7,873 69.02 3.02 62.6 7.0 0.19
1958 1,731 11.30 0.65 64.5 7.3 10,231 87.98 3.75 63.1 6.7 0.17
1961 2,067 12.94 0.74 65.0 7.3 12,402 103.88 4.32 64.1 5.8 0.17
1964 2,702 16.49 0.93 66.3 6.5 15,605 126.14 5.21 65.3 4.7 0.17
1967 2,835 17.05 0.89 67.2 6.3 16,990 134.62 5.34 66.3 4.2 0.17
1970 2,799 16.65 0.80 67.8 6.3 17,847 137.29 5.27 67.0 3.6 0.16
1973 2,861 16.57 0.82 68.4 6.3 19,136 140.68 5.64 67.9 2.9 0.15
1976 3,310 18.70 0.92 69.2 6.1 20,187 143.47 5.96 68.4 2.6 0.16
1979 3,680 20.57 1.04 69.9 6.1 20,574 143.50 6.29 68.8 2.5 0.18
1982 4,100 22.90 1.13 70.2 6.6 21,138 146.47 6.48 68.8 2.9 0.19
1985 4,537 25.14 1.25 70.4 7.4 21,662 147.58 6.77 68.5 3.8 0.21
1988 5,232 28.52 1.46 70.5 7.9 22,141 144.66 7.17 68.3 4.2 0.24
1991 7,218 30.72 1.50 70.1 8.7 27,720 139.81 6.89 67.7 4.6 0.26
1994 8,023 33.26 1.72 70.0 9.4 28,038 135.08 7.15 67.7 4.4 0.29
1997 8,754 35.20 1.92 69.8 10.0 28,424 130.51 7.41 68.0 4.4 0.31
2000 9,817 38.21 2.21 69.8 10.5 29,112 127.14 7.72 68.3 4.3 0.34
2003 10,626 40.15 2.35 69.8 10.9 28,632 119.69 7.42 68.8 4.1 0.37
2006 11,855 43.99 2.75 69.8 11.1 28,872 117.33 7.64 69.5 4.0 0.41
2009 13,088 48.44 2.94 70.1 11.1 29,132 117.46 7.33 70.2 4.2 0.45
2012 14,724 54.28 3.27 70.5 11.3 29,684 118.28 7.25 70.9 4.4 0.50
Death from cancer of the trachea, bronchus and lung; age ≥ 35 years, Federal Republic of Germany, since 1991 including death cases from West Germany and former East Germany; ICD-10 categories C33 and C34
(since 1998), ICD-8 and ICD-9 category 162 (1968–1997), ICD-6 and ICD-7 category 223 (1952–1967)
N number of deaths














Table 2 Lung cancer mortality and years of potential life lost
Trend 1 Trend 2 Trend 3 Trend 4 Trend 5
Years APC CI Years APC CI Years APC CI Years APC CI Years APC CI
Mortality rate per year
Women 1952–1960 3.3* 2.5 – 4.0 1960–1964 7.9* 4.3 – 11.6 1964–1972 −0.2 −1.1 – 0.7 1972–1987 3.6* 3.3 – 3.9 1987–2012 2.5* 2.4 – 2.7
Men 1952–1963 7.2* 6.9 – 7.5 1963–1968 2.3* 0.9 – 3.7 1968–1985 0.5* 0.3 – 0.6 1985–2006 −1.1* −1.2 – -1.0 2006–2012 0.2 −0.5 – 0.9
Lung cancer death cases/all death cases per year
Women 1952–1960 3.0* 2.0 – 4.0 1960–1964 7.6* 3.0 – 12.3 1964–1970 −3.2* −5.1 – -1.3 1970–2012 3.6* 3.5 – 3.6
Men 1952–1964 5.9* 5.5 – 6.2 1964–1969 0.2 −1.5 – 2.0 1969–1979 2.1* 1.5 – 2.6 1979–2001 0.9* 0.7 – 1.0 2001–2012 −0.4* −0.8 – -0.0
Years of potential life lost
Women 1952–1960 1.1* 0.2 – 2.0 1960–1964 −3.6 −7.3 – 0.3 1964–1978 −0.6* −1.0 – -0.2 1978–1997 2.9* 2.6 – 3.1 1997–2012 0.8* 0.4 – 1.1
Men 1952–1959 −2.1* −3.2– -0.9 1959–1978 −5.1* −5.4 – -4.8 1978–1989 6.4* 5.7 – 7.1 1989–2006 −1.0* −1.4 – -0.7 2006–2012 1.4 −0.1 – 2.9
Taxed tobacco products
1952–1971 3.5* 3.3–3.8 1971–1989 −0.7* −1.0 – -0.3 1989–1993 −4.1 −12.5 – 5.2 1993–2001 0.6 −0.6 – 1.8 2001-2012 −3.4* −4.0 – -2.8
Trends from 1952 to 2012 according to joinpoint analysis
APC annual percent change
CI 95 % Confidence Interval













The proportions of respondents who had started smoking
before the age of 18 increased from 21.3 % in 1989 to
48.9 % in 2009 among female ever smokers and from
35.3 % in 1989 to 57.2 % in 2009 among male ever
smokers. The proportion of female ever daily smokers
who smoked more than 20 cigarettes per day was 15.0 %
in 1989 and remained in the range of 11.1 % to 12.9 %
thereafter. Among male ever daily smokers this was
29.3 % in 1989 and subsequently remained within the
range of 22.0 % to 24.8 %. Quit rates increased from
37.3 % in 1989 to 46.5 % in 2009 and from 46.0 % in 1989
to 53.6 % in 2009 among female and male ever smokers
respectively.
Discussion
The present study’s two main outcomes were the sex-
specific trends in lung cancer mortality and in YPLL.
The lung cancer mortality rate among females increased
over 61 years of observation while it gradually decreased
after 1985 and later stabilized among males. The number
of lung cancer deaths as a proportion of total deaths was
on the rise in both genders and among all age groups for
the majority of the period studied. No clear long-term
decrease could be observed except a slight reduction
among men after 2001 — although this amounted to less
than one annual percentage point. Furthermore, lung
cancer deaths as a proportion of total mortality rose
more for women than for men in all age groups as the
ratio of female to male lung cancer deaths rose from 0.2
to 0.5.
These results correspond with findings from other
European countries, as previous work has also shown in-
creases in female lung cancer mortality [1, 22, 23]. Fur-
thermore, it has been demonstrated using data from
national health surveys and cancer registries that there
was increase in smoking-attributable cancer incidence
among women in Germany between 1999 and 2008 [24].
These findings, however, should be considered in the
context of recent research that has revealed that the
relative risk of death from lung cancer among female
smokers is equal to that of male smokers [12].
There is some reason to suppose that females may
have converged with males in terms of lifetime tobacco
consumption [12]. During the twenty years following
1989, the proportion of smokers among females in the
general population remained stable at 18 to 19 %
whereas among men it decreased by 9.2 percentage
points. Within this period, the proportion of those who
started smoking before the age of 18 among female ever
smokers increased considerably from 21 % to 49 % and
from 35 to 57 % among males.
Among European countries, Germany has been shown
to make weakest efforts in preventing tobacco-related
disease [25]. Our findings are plausible in light of the
evidence that has revealed decreasing or at least stabiliz-
ing female lung cancer rates in countries with compre-
hensive tobacco control programs [26, 27].
In Germany, the increase in lung cancer mortality in
men decelerated since the 1970s and stopped after 1985
despite a lack of meaningful prevention efforts. One rea-
son may be that efforts to curb the smoking epidemic in
one country may also have effects on social norms sur-
rounding smoking in other countries. A significant re-
duction in exposure to other lung cancer risk factors
such as asbestos is an unlikely cause, given that it was
only since the 1990s that exposure to asbestos in
Germany has been reduced because of legal measures.
YPLL rose during most of the study years from 6.6 in
1952 to 11.3 in 2012 among females who died of lung
cancer, with the trend continuing to 2012. YPLL among
females also exceeded that among males. One reason for
this trend among women may be that age at death in the
general female population increased more than age at
death among lung cancer cases. This gap widened more
among women than among men. Age at death from


























a1 cigarette equivalent = 1 cigarette or 0.5 cigar or small cigar or 1 g rolled or
pipe tobacco [18]
bNumber of cigarette equivalents per calendar year divided by number of
residents at age 15 or older per calendar year. Since 1960 Federal State of
Saarland included, since 1991 East Germany (5 Federal States plus East Berlin)
included [17]
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Table 4 Tobacco smoking
Survey Women Men
Year N General population:
% current smokers
Ever smokers: % age
of onset < 18
Ever daily smokers:
% cpd > 20
Ever smokers:
% former smokers
N General population: %
current smokers
Ever smokers: % age
of onset < 18
Ever daily smokers:
% cpd > 20
Ever smokers: %
former smokers
1989 58,318 17.9 21.3 15.0 37.3 48,235 36.7 35.3 29.3 46.0
1995 78,928 17.9 30.0 12.6 39.6 67,388 33.0 41.8 24.5 48.3
1999 74,115 19.2 37.9 12.9 42.3 64,249 32.2 49.2 24.8 49.7
2003 76,127 19.2 45.0 11.7 43.7 67,185 30.2 54.3 23.5 50.6
2005 160,587 19.4 46.2 12.5 44.1 142,129 28.8 54.6 24.6 52.0
2009 167,349 18.9 48.9 11.1 46.5 148,711 27.5 57.2 22.0 53.6
Survey: microcensus. A random subsample of 70 % of the participants in the microcensus was obtained for each of the years 1989, 1995, 1999, 2003, 2005, 2009
N Number of persons among the national population at age 35 or older who received the question whether being a current, former or never smoker. For scientific purposes a random subsample of 70 % of the
participants in the microcensus was available for each of the years













causes other than lung cancer in the general population
increased by 11.4 years among females over the study
period and by 6.4 years among males. Females in the
general population are more likely than males to follow
a healthy lifestyle as previous work shows that females
use healthcare services more often, drink less alcohol
and are less likely to be overweight [28]. Our YPLL re-
sults correspond to data from Canada where 13.9 YPLL
had been found for females and 6.8 YPLL for males
among lung cancer cases [9]. The increase of the pro-
portion of smokers who started smoking before age 18
among ever smokers was stronger for women than for
men. Although this may have resulted from higher to-
bacco consumption among women, it seems unlikely
that exposure to carcinogens associated with lung cancer
other than tobacco smoke has increased more among
women than among men.
YPLL among females increased despite increases in
the mean age at death among lung cancer cases. Reasons
for the rise in age at lung cancer death may include im-
provements in medical care for both lung cancer and
other diseases. Lung cancer detection may also have
been improved. However, it must also be considered that
even among patients aged 45 to 54 years no more than
37 % of females and 31 % of males diagnosed with lung
cancer survive longer than two years in Germany [29].
The increase in the mean age of death among lung can-
cer cases may be partly attributable to decreases in heart
and circulatory disease mortality, resulting in more indi-
viduals surviving to older ages than previously.
The decrease in YPLL among males may partly be ex-
plained by a smaller increase of mean age at death
among males than among the females in the general
population aged 35 or older and without lung cancer.
This decrease among males also reflects poorer health
behaviors and health care use among men than among
women in the general population [28]. This may be
reflected in previous studies which show fewer YPLL
among male than female cancer cases [30].
Our data had four primary limitations, however. First,
misclassification of lung cancer cases may have occurred,
particularly due to failure to correctly identify lung can-
cer as the cause of death. Second, only data for the
Federal Republic of Germany were available until 1990,
because no data could be obtained for the former
German Democratic Republic. Third, adequate survey
data on smoking behavior was unavailable before
1989. Finally, no precise estimation of population or
individual-level exposure to tobacco smoke carcinogens
could be provided. In the 1960s, marketing of filter ciga-
rettes increased [31]. This is relevant given the extensive
promotion of “light” cigarettes during the period studied,
which were intended to appeal to women. However,
smokers may compensate for their lower nicotine content
by smoking the same number of cigarettes more intensely
or smoking more cigarettes per day.
Conclusions
Lung cancer mortality, and YPLL among cases aged 35
or older have all increased among women over the pre-
vious six decades without any period of significant or
long-term decrease. During this period, women also rep-
resented a growing proportion of lung cancer deaths
among all death cases. Probable explanations for these
findings include increasing tobacco consumption among
women alongside declining smoking rates among men.
Women are likely to have caught up with men in terms
of their smoking patterns and lifetime exposure to to-
bacco smoke. Public health efforts should consider the
time lag in the tobacco epidemic among women com-
pared to men.
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